Hjem › Multipelt myelom › Virginia
Multipelt myelom kliniske forsøg i Virginia
20 studier for Multipelt myelom søger deltagere på steder i Virginia.
Byer i Virginia
Officiel studietekst (engelsk)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Gainesville
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07391657A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Virginia Commonwealth University - Massey Cancer Center, Richmond
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06500884A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Charlottesville
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07073547A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Alexander T. Augusta Military Medical Center, Fort Belvoir
- Virginia Oncology Associates Brock Cancer Center, Norfolk
- Richmond VA Medical Center, Richmond
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05552222A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Virginia Cancer Specialists - Fairfax /ID# 278716, Fairfax
- Blue Ridge Cancer Care - Roanoke /ID# 278722, Roanoke
RekruttererFase 2/3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Inova Schar Cancer Institute, Fairfax
RekruttererFase 2
Alder 12 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT02693535Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
- VCU Massey Comprehensive Cancer Center, Richmond
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06465316Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Oncology Associates, Norfolk
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT06297226AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Fairfax
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT06106945AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlottesville
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Fairfax
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT07764978A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Virginia Cancer Specialists - Fairfax /ID# 268559, Fairfax
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT05650632Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Sovah Health Martinsville, Martinsville
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- og 2 flere
RekruttererFase 3
Alle aldre · Alle køn · Opdateret 10. jun. 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Virginia Oncology Associates, Norfolk
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- Virginia Oncology Associates, Norfolk
RekruttererFase 2
Alder 19 og opefter · Alle køn · Opdateret 4. jun. 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Fairfax
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT06679101Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Virginia Cancer Specialists, Fairfax
- Blue Ridge Cancer Center, Roanoke
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT05972135A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
- Virginia Oncology Associates, Norfolk
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 24. mar. 2026 · NCT04988555CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- Virginia Commonwealth University, Richmond
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2025 · NCT05722418IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- NEXT Oncology Virginia, Fairfax
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 3. jun. 2025 · NCT06119685Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.